CARsgen Therapeutics (HKG:2171) widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.
Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.
Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.
The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.